In the Press

Filters
Type
Sectors
Geography
Companies

Sign up for our free
equity research notes

Register
1622 Results
Embed
Matthew Read comments on shareholder democracy victory in Portfolio Adviser

Matthew Read comments on shareholder democracy victory for USA in Patrick Sanders’ article: “There is nothing wrong with shareholder activism when it holds underperforming boards to account, but repeatedly pursuing an agenda that almost all other shareholders oppose is another matter.” Read the article here

Matthew Read comments on Baillie Gifford’s USA win in Mail

Matthew Read comments on USA’s AGM result in Angharad Carrick’s article: “This is a victory for common sense and shareholder democracy.” Read the article here

Matthew Read comments on MNKS in Investors’ Chronicle

Matthew Read comments on MNKS’ investing process in Holly McKechnie’s article: “This reflects the strength of the manager’s process and access to strong private companies such as SpaceX (US:SPCX) and its recent purchase of Anthropic,” Read the article here

Richard Williams comments on AUSC and merger in Portfolio Adviser

Richard Williams comments on AUSC results and merger with JUGI in Patrick Sanders’ article: “While UK smaller companies have faced a challenging backdrop, the board acknowledges that stock selection, rather than sector positioning, was primarily responsible for the shortfall.” Read the article here

Matthew Read comments on MTE tender in Investment Week

Matthew Read comments on sentiment and MTE’s approach in Robin Amos’ article: “There are tentative signs that sentiment is improving, and Montanaro’s emphasis on high-quality, profitable businesses should leave it well placed to benefit if the recovery gathers momentum.” Read the article here

Biotech trusts top performance charts in February
Matthew Read comments on possible clean exit for USF in Investment Week

Matthew Read comments on USF’s wind-down and possible buyer in Robin Amos’ article: “With USF in wind-down, a clean exit with greater certainty over the proceeds, rather than an earn-out arrangement, also has to be preferable at this stage. That said, regulatory approval could take up to five months and while the progress on due […]

Biotech trusts top performance charts in February
Richard Williams comments on Scottish Oriental review in Portfolio Adviser

Richard Williams comments on the SST tender being cancelled in Patrick Sanders’ article: “Consolidation now looks a distinct possibility.” Read the article here

Richard Williams comments on the proxy advisers’ verdict on USA and Saba

Richard Williams comments on the proxy advisers’ recommendation to vote against Saba in Michael Nelson’s article: “However, proxy adviser recommendations are not binding, and Saba’s voting power means much will depend on the participation of other shareholders, making turnout crucial if the board is to fend off the challenge,” Read the article here

Biotech trusts top performance charts in February
Matthew Read comments on SSIT’s new investment in Investment Week

Matthew Read comments on SSIT’s further investment in Skylo in Robin Amos’ article: “Ultimately, Skylo will still need to translate its technological promise into sustained commercial success, but the investment also illustrates how the C share fundraising has given SSIT the firepower to stand its corner during fundraisings for promising holdings rather than risk dilution […]

Biotech trusts top performance charts in February
Matthew Read comments on Saba’s NBPE stake in Portfolio Adviser

Matthew Read comments on NBPE’s strategy in the face of Saba in Patrick Sanders’ article: “Given that NBPE has been generating meaningful realisations and recycling capital into new opportunities, we think there remains a credible case for allowing the existing strategy to run its course,” Read the article here